A Unique AIDS Vaccine Candidate For Multiple HIV Strains

描述：（申请人提供）开发安全有效的艾滋病 疫苗具有巨大的商业潜力和社会影响，是一种国家 要务针对艾滋病疫苗开发中存在的障碍， 一套新的概念和设计是综合开发一种新的艾滋病 疫苗佐剂系统它包括免疫原HMP-gp 120的特殊设计， 两种靶向B淋巴细胞的新佐剂和一种新的疫苗制剂 抗原佐剂。这可能会导致一种长期寻求的艾滋病疫苗， 有效和持久的中和抗体反应， 预防艾滋病毒感染和传播。在拟议的第一阶段， 研究我们将开发一种新的艾滋病疫苗佐剂系统，免疫动物， 检测阻断HIV gp 120的一般和中和抗体活性 与DC-SIGN绑定。研究人员的经验，初步数据， 动物设施和公司的专业知识使科学团队能够胜任 以完成本提案中的目标。我们预计这种新型艾滋病 疫苗-佐剂系统将诱导强烈的中和抗体活性， 为难以捉摸的疫苗提供了一个模型，并为增强体液免疫提供了一种新的机制。 免疫力构建的HMP-gp 120、新佐剂和其他试剂将在本发明中公开。 第二阶段研究的基础。中和抗体活性将提供 第二阶段研究和开发所需的信息。

DESCRIPTION: (Provided by Applicant) Development of a safe and effective AIDS vaccine has tremendous commercial potential and social impact and is a national priority. In response to the obstacles presented in AIDS vaccine development, a set of new concepts and designs is integrated to develop a new AIDS vaccine-adjuvant system. It includes a special design of immunogen HMP-gpl20, two novel adjuvants targeting B lymphocytes, and a new formulation of vaccine antigen-adjuvant. It could lead to a long-sought AIDS vaccine that elicits effective and long lasting neutralizing antibody responses to multiple HIV strains to prevent HIV infection and transmission. In the proposed Phase I study we will develop a new AIDS vaccine-adjuvant system, immunize animals, and detect general and neutralizing antibody activities that block HIV gpl20 binding to DC-SIGN. The investigators' experience, the preliminary data, the animal facility, and the company expertise make the scientific team competent to complete the objectives in this proposal. We anticipate that this novel AIDS vaccine-adjuvant system will induce strong neutralizing antibody activity and provide a model for elusive vaccines and a novel mechanism to enhance humoral immunity. The constructed HMP-gpl20, new adjuvants, and other reagents will be the basis for Phase II study. The neutralizing antibody activity will provide necessary information for phase II research and development.